PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28770489-1	2017	PURPOSE: We developed simulation and modeling methods to predict the in vivo pharmacokinetic profiles of acyclovir, following escalating oral doses of valacyclovir, in wildtype and Pept1 knockout mice.	Acyclovir	105-114	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	181-186	
23924683-2	2013	A secondary aim was to characterize the role of PepT1 on the tissue distribution of its active metabolite, acyclovir.	Acyclovir	107-116	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	48-53	
23264448-1	2013	The purpose of this study was to quantitatively determine the contribution of PepT1 [peptide transporter 1 (SLC15A1)] to the intestinal permeability of valacyclovir, an ester prodrug of the antiviral drug acyclovir.	Acyclovir	155-164	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	78-83	
23264448-1	2013	The purpose of this study was to quantitatively determine the contribution of PepT1 [peptide transporter 1 (SLC15A1)] to the intestinal permeability of valacyclovir, an ester prodrug of the antiviral drug acyclovir.	Acyclovir	155-164	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	85-106	
23264448-1	2013	The purpose of this study was to quantitatively determine the contribution of PepT1 [peptide transporter 1 (SLC15A1)] to the intestinal permeability of valacyclovir, an ester prodrug of the antiviral drug acyclovir.	Acyclovir	155-164	solute carrier family 15 (oligopeptide transporter), member 1	Mus musculus	108-115